Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected ...

Replit expects to hit $1 billion in revenue next year as AI coding products replace old tools.

Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory ...

Our client is a global leader in digital marketing and client reporting solutions, empowering financial professionals to enhance investor engagement and retention. With operations spanning four ...

For months, Eline Van der Velden, founder of AI production studio Particle6, had been taking meetings around town and introducing her ingenue, Tilly Norwood. She made no secret of her hopes for the 20 ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...